Barclays Portfolio holdings
Barclays is a British universal bank whose roots go back to 1690, when the Quakers John Freame and Thomas Gould started a goldsmith banking business in London. The Barclays name came into the business in 1736, when James Barclay, son-in-law of founder John Freame, became a partner. Barclays launched the UK's first credit card, Barclaycard, in 1966, and in 1967 put the world's first cash machine in a branch in Enfield. In 2008 Barclays bought the North American operations of Lehman Brothers, and in 2009 it sold its Barclays Global Investors unit, home of the iShares ETFs, to BlackRock. It runs five divisions: UK consumer banking, UK corporate banking, private banking and wealth management, an investment bank and a US consumer bank.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$17.5B |
| 2 |
NVIDIA
NVDA
|
+$2.7B |
| 3 |
Intel
INTC
|
+$1.98B |
| 4 |
Broadcom
AVGO
|
+$1.46B |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$1.11B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$35.8B |
| 2 |
Apple
AAPL
|
+$1.83B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$913M |
| 4 |
Microsoft
MSFT
|
+$856M |
| 5 |
Bank of America
BAC
|
+$792M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 49.47% |
| 2 | Technology | 19.84% |
| 3 | Consumer Discretionary | 7.61% |
| 4 | Financials | 5.61% |
| 5 | Communication Services | 3.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4101
Dave & Buster's
PLAY
$283M
| $144K | ﹤0.01% |
22,511
+10,403
| +86% | +$97.2K |
2016 Q2
41 quarters
|
|
4102
Vanguard FTSE All-World ex-US Small-Cap Index Fund
VSS
$11.2B
| $144K | ﹤0.01% |
925
| – | – |
2019 Q2
29 quarters
|
|
4103
Main Street Capital
MAIN
$5.33B
| $143K | ﹤0.01% |
2,600
-41,462
| -94% | -$2.32M |
2024 Q2
9 quarters
|
|
4104
Akebia Therapeutics
AKBA
$155M
| $143K | ﹤0.01% |
155,290
+26,932
| +21% | +$29K |
2024 Q1
10 quarters
|
|
4105
PUT
Genmab
GMAB
$32.8B
| $143K | ﹤0.01% |
+4,000
| New | +$127K |
2026 Q3
0 quarters
|
|
4106
Intrepid Potash
IPI
$442M
| $142K | ﹤0.01% |
4,439
-994
| -18% | -$36.1K |
2022 Q1
18 quarters
|
|
4107
Cooper-Standard Automotive
CPS
$340M
| $142K | ﹤0.01% |
6,814
-9,878
| -59% | -$263K |
2014 Q1
50 quarters
|
|
4108
Pangaea Logistics
PANL
$583M
| $142K | ﹤0.01% |
17,677
+6,055
| +52% | +$46.7K |
2022 Q3
16 quarters
|
|
4109
Black Rock Coffee Bar Inc
BRCB
$199M
| $142K | ﹤0.01% |
19,879
+15,803
| +388% | +$128K |
2025 Q3
4 quarters
|
|
4110
ProKidney
PROK
$236M
| $142K | ﹤0.01% |
85,332
+69,211
| +429% | +$117K |
2023 Q2
13 quarters
|
|
4111
PGIM AAA CLO ETF
PAAA
$15.3B
| $141K | ﹤0.01% |
+2,756
| New | +$142K |
2026 Q3
0 quarters
|
|
4112
InMode
INMD
$785M
| $140K | ﹤0.01% |
9,895
-6,187
| -38% | -$92.4K |
2022 Q1
18 quarters
|
|
4113
WW International
WW
$132M
| $140K | ﹤0.01% |
9,040
+5,979
| +195% | +$92.4K |
2025 Q3
4 quarters
|
|
4114
Fermi Inc
FRMI
$1.2B
| $139K | ﹤0.01% |
33,134
-21,019
| -39% | -$125K |
2025 Q4
3 quarters
|
|
4115
Inhibikase Therapeutics
IKT
$222M
| $139K | ﹤0.01% |
67,839
+48,114
| +244% | +$109K |
2024 Q4
7 quarters
|
|
4116
Invesco DB Base Metals Fund
DBB
$355M
| $139K | ﹤0.01% |
5,505
| – | – |
2025 Q4
3 quarters
|
|
4117
GMR Solutions Inc
GMRS
$643M
| $139K | ﹤0.01% |
14,461
+10,843
| +300% | +$141K |
2026 Q2
1 quarter
|
|
|
QMMM
4118
DELISTED
QMMM Holdings
QMMM
| $139K | ﹤0.01% |
+1,163
| New | +$139K |
2026 Q3
0 quarters
|
|
4119
Clearwater Paper
CLW
$226M
| $139K | ﹤0.01% |
7,229
-10,556
| -59% | -$208K |
2013 Q2
53 quarters
|
|
4120
Titan America SA
TTAM
$2.13B
| $137K | ﹤0.01% |
10,039
+1,260
| +14% | +$19.7K |
2025 Q2
5 quarters
|
|
4121
Core Molding Technologies
CMT
$190M
| $137K | ﹤0.01% |
6,012
+2,920
| +94% | +$70.9K |
2023 Q1
14 quarters
|
|
4122
Paysafe
PSFE
$352M
| $137K | ﹤0.01% |
24,293
+19,210
| +378% | +$138K |
2022 Q1
18 quarters
|
|
4123
Mayville Engineering Co
MEC
$358M
| $137K | ﹤0.01% |
9,101
-1,096
| -11% | -$26.4K |
2019 Q2
29 quarters
|
|
4124
Aardvark Therapeutics
AARD
$36.3M
| $136K | ﹤0.01% |
25,792
+23,533
| +1,042% | +$144K |
2025 Q2
5 quarters
|
|
4125
AllianzIM U.S. Equity Buffer20 Jul ETF
JULW
$254M
| $135K | ﹤0.01% |
3,263
| – | – |
2025 Q4
3 quarters
|
|
Similar funds
Barclays's Q3 2026 Portfolio in Review
As of Q3 2026, Barclays held 5,855 positions worth $500B, down 4% from $521B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Barclays withdrew a net $19B in Q3 2026, closing 474 positions and reducing 1,494 holdings. Its most notable exit was ExxonMobil, an estimated $761M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, down from 55% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Barclays opened a new position in iShares Broad USD High Yield Corporate Bond ETF worth $199M.
- Barclays's largest Q3 2026 buy was iShares Broad USD High Yield Corporate Bond ETF: 5,582,517 shares worth $199M.
- Barclays added most to Tesla in Q3 2026, an estimated $17.5B increase.
- Barclays's biggest Q3 2026 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $35.8B.
- Barclays fully exited ExxonMobil in Q3 2026, selling an estimated $761M.
- Barclays's ten largest holdings make up 40% of its $500B portfolio in Q3 2026.
- Barclays opened 525 new positions and closed 474 in Q3 2026.
- Barclays's portfolio value fell 4% quarter-over-quarter to $500B.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.